Literature DB >> 11156560

Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.

A Sugidachi1, F Asai, K Yoneda, R Iwamura, T Ogawa, K Otsuguro, H Koike.   

Abstract

1. CS-747 is a novel thienopyridine-type platelet ADP inhibitor which lacks in vitro activity. This study examined pharmacological profiles of R-99224, a hepatic metabolite of CS-747. 2. R-99224 produced a concentration-dependent inhibition of in vitro platelet aggregation in washed human platelets (0.03 - 1 microg ml(-1)), which was relatively specific to ADP compared to collagen and thrombin. 3. R-99224 (0.1 - 3 microg ml(-1)) also elicited a similar inhibition of ADP-induced aggregation in rat platelets. The inhibition by R-99224 (10 microg ml(-1)) persisted even after platelets were washed three times. Intravenous injection of R-99224 (0.1 - 3 mg kg(-1)) to rats resulted in a dose-dependent inhibition of ex vivo ADP-induced platelet aggregation. 4. R-99224 (0.1 - 100 microM) decreased binding of [(3)H]-2-methylthio-ADP ([(3)H]-2-MeS-ADP), a stable ligand for platelet ADP receptors, to washed human platelets. The inhibition by R-99224 reached a plateau at a concentration of 3 microM (1.4 microg ml(-1)), but complete inhibition was not achieved even at the highest concentration used (100 microM). 5. R-99224 (10 microM) in combination with ARL-66096 (0.3 microM), an ATP analogue-type G(i)-linked P2T receptor antagonist, produced no additional inhibition of [(3)H]-2-MeS-ADP binding. In contrast, [(3)H]-2-MeS-ADP binding was completely abolished by R-99224 (10 microM) in combination with A3P5PS (300 microM), a selective P2Y(1) antagonist, suggesting that R-99224 selectively binds to the G(i)-linked P2T receptor. 6. R-99224 (0.01 - 3 microg ml(-1)) inhibited ADP-induced [(125)I]-fibrinogen binding to human platelets in a concentration-dependent manner. R-99224 (0.1 - 1 microg ml(-1)) also inhibited the ADP-induced decrease in cyclic AMP levels in PGE(1)-stimulated platelets, whereas the agent did not affect ADP (10 microM)-induced Ca(2+) mobilization. 7. These findings suggest that R-99224 is a selective and irreversible antagonist of G(i)-linked P2T receptors and that R-99224 is a responsible molecule for in vivo actions of CS-747.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11156560      PMCID: PMC1572523          DOI: 10.1038/sj.bjp.0703761

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

Review 1.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

2.  Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.

Authors:  J E Fabre; M Nguyen; A Latour; J A Keifer; L P Audoly; T M Coffman; B H Koller
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

Review 3.  Receptors for ADP on human blood platelets.

Authors:  S M Hourani; D A Hall
Journal:  Trends Pharmacol Sci       Date:  1994-04       Impact factor: 14.819

4.  Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets.

Authors:  A B MacKenzie; M P Mahaut-Smith; S O Sage
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

5.  Megakaryocytopoiesis and platelet production are stimulated during late pregnancy and early postpartum in the rat.

Authors:  C W Jackson; S A Steward; R A Ashmun; T P McDonald
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

6.  Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.

Authors:  A A Weber; S Reimann; K Schrör
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

7.  ADP can induce aggregation of human platelets via both P2Y(1) and P(2T) receptors.

Authors:  G E Jarvis; R G Humphries; M J Robertson; P Leff
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 8.  Clopidogrel.

Authors:  A J Coukell; A Markham
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

9.  Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.

Authors:  J Jin; S P Kunapuli
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.

Authors:  M S Fagura; I A Dainty; G D McKay; I P Kirk; R G Humphries; M J Robertson; I G Dougall; P Leff
Journal:  Br J Pharmacol       Date:  1998-05       Impact factor: 8.739

View more
  19 in total

1.  ADP and platelets: the end of the beginning.

Authors:  D Woulfe; J Yang; L Brass
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 2.  Molecular recognition at purine and pyrimidine nucleotide (P2) receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Michihiro Ohno; Bhalchandra V Joshi; Pedro Besada; Bin Xu; Susanna Tchilibon
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

3.  Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.

Authors:  V L Serebruany; M G Midei; H Meilman; A I Malinin; D R Lowry
Journal:  Postgrad Med J       Date:  2006-06       Impact factor: 2.401

4.  Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus.

Authors:  Ricardo J Rodrigues; Teresa Almeida; Peter J Richardson; Catarina R Oliveira; Rodrigo A Cunha
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

Review 5.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

6.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

7.  Potassium 2-(1-hydroxypentyl)-benzoate inhibits ADP-induced rat platelet aggregation through P2Y1-PLC signaling pathways.

Authors:  Hongyan Yang; Shaofeng Xu; Jiang Li; Ling Wang; Xiaoliang Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-03-19       Impact factor: 3.000

8.  A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.

Authors:  Joseph A Jakubowski; Nobuko Matsushima; Fumitoshi Asai; Hideo Naganuma; John T Brandt; Takashi Hirota; Stephen Freestone; Kenneth J Winters
Journal:  Br J Clin Pharmacol       Date:  2006-10-31       Impact factor: 4.335

9.  Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.

Authors:  L Testa; G G L Biondi Zoccai; M Valgimigli; R A Latini; S Pizzocri; S Lanotte; M L Laudisa; N Brambilla; M R Ward; G A Figtree; F Bedogni; R Bhindi
Journal:  Adv Hematol       Date:  2010-12-05

10.  Identification of the active metabolite of ticlopidine from rat in vitro metabolites.

Authors:  Kenji Yoneda; Ryou Iwamura; Hiroko Kishi; Yoichi Mizukami; Kimiko Mogami; Sei Kobayashi
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.